{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:18:50Z","timestamp":1783138730556,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2025AFD824"],"award-info":[{"award-number":["2025AFD824"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.transproceed.2026.03.019","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:33:44Z","timestamp":1776944024000},"page":"800-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Therapy of Myelofibrosis"],"prefix":"10.1016","volume":"58","author":[{"given":"Xiaojin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.transproceed.2026.03.019_bib0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.revmed.2020.08.018","article-title":"[Myelofibrosis: a review]","volume":"42","author":"Genthon","year":"2021","journal-title":"Rev Med Interne"},{"issue":"2","key":"10.1016\/j.transproceed.2026.03.019_bib0002","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000101708","article-title":"Myelofibrosis\u2013what's in a name? Consensus on definition and EUMNET grading","volume":"74","author":"Thiele","year":"2007","journal-title":"Pathobiology"},{"issue":"5","key":"10.1016\/j.transproceed.2026.03.019_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI19540","article-title":"TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia","volume":"113","author":"Shehata","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transproceed.2026.03.019_bib0004","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.2147\/CMAR.S258875","article-title":"Patients of myelodysplastic syndrome with mild\/moderate myelofibrosis and a monosomal karyotype are independently associated with an adverse prognosis: long-term follow-up data","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"22","key":"10.1016\/j.transproceed.2026.03.019_bib0005","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood.V128.22.5486.5486","article-title":"High frequency of loss of heterozygosity and chromosomal imbalances in patients with myelofibrosis","volume":"128","author":"Junior","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.transproceed.2026.03.019_bib0007","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","article-title":"A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis","volume":"121","author":"Mascarenhas","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transproceed.2026.03.019_bib0008","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/187152912801823174","article-title":"Current and emerging therapies in primary myelofibrosis","volume":"12","author":"Ayyappan","year":"2012","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"8","key":"10.1016\/j.transproceed.2026.03.019_bib0010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/13543784.2012.693913","article-title":"Immunomodulatory agents in myelofibrosis","volume":"21","author":"Tabarroki","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.transproceed.2026.03.019_bib0011","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.transproceed.2026.03.019_bib0012","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.27274","article-title":"2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"99","author":"Ali","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.transproceed.2026.03.019_bib0013","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/ajh.26349","article-title":"2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"96","author":"Ali","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.transproceed.2026.03.019_bib0014","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-021-01222-z","article-title":"Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT","volume":"56","author":"Battipaglia","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.transproceed.2026.03.019_bib0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-022-01865-6","article-title":"Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis","volume":"58","author":"Luo","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2026.03.019_bib0016","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bbmt.2018.04.019","volume":"24","author":"Sharma","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2026.03.019_bib0017","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjh.15952","article-title":"Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis","volume":"186","author":"Mannina","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.transproceed.2026.03.019_bib0018","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2026.03.019_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-024-05080-3","article-title":"Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Zhu","year":"2024","journal-title":"J Transl Med"},{"issue":"3, Supplement","key":"10.1016\/j.transproceed.2026.03.019_bib0022","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.bbmt.2019.12.609","article-title":"Outcome of allogenic hematopoietic stem cell transplantation in myelofibrosis: a single-center retrospective analysis","volume":"26","author":"Choudhary","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2026.03.019_bib0023","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/TCRM.S258704","article-title":"Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate\/high-risk myelofibrosis: evidence to date","volume":"16","author":"Bassiony","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.transproceed.2026.03.019_bib0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11899-017-0403-0","article-title":"Novel therapies for myelofibrosis","volume":"12","author":"Pettit","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.transproceed.2026.03.019_bib0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","article-title":"How I treat myelofibrosis after failure of JAK inhibitors","volume":"132","author":"Pardanani","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transproceed.2026.03.019_bib0026","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.transproceed.2026.03.019_bib0027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbmt.2017.10.037","article-title":"Transplant decisions in patients with myelofibrosis: should mutations be the judge?","volume":"24","author":"Salit","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0028","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/hematology.2023000453","article-title":"Are transplant indications changing for myelofibrosis?","volume":"2023","author":"Palmer","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1016\/j.transproceed.2026.03.019_bib0029","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.transproceed.2026.03.019_bib0031","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajh.26042","article-title":"Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: the role of the conditioning regimen","volume":"96","author":"Chiusolo","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.transproceed.2026.03.019_bib0032","doi-asserted-by":"crossref","first-page":"770.e771","DOI":"10.1016\/j.jtct.2023.09.013","article-title":"Transplantation outcomes of myelofibrosis with busulfan and fludarabine myeloablative conditioning","volume":"29","author":"Joseph","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.transproceed.2026.03.019_bib0033","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood-2023-190449","article-title":"A pilot study of reduced intensity HLA-haploidentical hematopoietic cell transplantation (HaploHCT) with post-transplant cyclophosphamide in patients with advanced myelofibrosis","volume":"142","author":"Ali","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transproceed.2026.03.019_bib0034","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3390\/cancers7040903","article-title":"Acute myeloid leukemia with isolated trisomy 19 associated with diffuse myelofibrosis and osteosclerosis","volume":"7","author":"Stelling","year":"2015","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.transproceed.2026.03.019_bib0035","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","article-title":"Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis","volume":"35","author":"Kr\u00f6ger","year":"2007","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.transproceed.2026.03.019_bib0036","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","article-title":"Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis","volume":"20","author":"Kr\u00f6ger","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2026.03.019_bib0037","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2026.03.019_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030898","article-title":"Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transproceed.2026.03.019_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1205387","article-title":"Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes","volume":"13","author":"Jungius","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.transproceed.2026.03.019_bib0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-016-0321-y","article-title":"Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study","volume":"9","author":"Ruggeri","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.transproceed.2026.03.019_bib0041","doi-asserted-by":"crossref","first-page":"687.e681","DOI":"10.1016\/j.jtct.2023.08.020","article-title":"Adoptive immunotherapy via donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for myelofibrosis: a real-world, retrospective multicenter study","volume":"29","author":"Rampotas","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.transproceed.2026.03.019_bib0042","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","article-title":"Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"59","author":"Oechsler","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.transproceed.2026.03.019_bib0043","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2026.03.019_bib0044","doi-asserted-by":"crossref","first-page":"1011.e1011","DOI":"10.1016\/j.jtct.2024.07.026","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.transproceed.2026.03.019_bib0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.transproceed.2026.03.019_bib0046","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transproceed.2026.03.019_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13904","article-title":"Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Mizuno","year":"2022","journal-title":"Transpl Infect Dis"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526001685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134526001685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:48:15Z","timestamp":1783136895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134526001685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0041134526001685"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.03.019","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Therapy of Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2026.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}